17 May 2011
Responding to the decision by NICE not to recommend Everolimus as a treatment for advanced kidney cancer, Mike Hobday, Head of Policy at Macmillan Cancer Support, said:
'This is very disappointing news for cancer patients with advanced kidney cancer, who have repeatedly lost out on getting drugs on the NHS. Drugs for rarer cancers are often more expensive as they can be harder to develop and are intended for smaller populations.
'It must be remembered that a person needing a drug is someone’s sister, someone’s son, someone’s mother – who would deny them the chance of a longer or better quality of life? Everyone should get the cancer drugs their doctor recommends, regardless of what type of cancer they have or where they live.
'It is crucial that the £200 million Cancer Drugs Fund prioritises drugs for rarer cancers, like advanced kidney cancer so no more cancer patients miss out on the drugs they so desperately need.'
For cancer support at home, over the phone, call the Macmillan Support Line free on 0808 808 00 00 (Monday to Friday, 9am – 8pm) or visit www.macmillan.org.uk/cancerdrug
For further information, please contact:
Julie Wills, Media & PR Officer (Assistant), Macmillan Cancer Support
020 7840 4933
Notes to Editors:
In August 2009, NICE rejected the following kidney cancer drugs for the treatment of advanced and/or metastatic renal cell carcinoma:
- bevacizumab, trade name Avastin, for first-line treatment
- sorafenib, trade name Nexavar, for first and second-line treatment
- sunitinib, trade name Sutent, for second-line treatment (only accepted as first line)
- temsirolimus, trade name Torisel, for first-line treatment
About Macmillan Cancer Support
Macmillan Cancer Support improves the lives of people affected by cancer, providing practical, medical, emotional and financial support. Working alongside people affected by cancer, Macmillan works to improve cancer care. One in three of us will get cancer. Two million of us are living with it. If you are affected by cancer Macmillan can help.
Call the Macmillan Support Line on 0808 808 00 00, Monday to Friday, 9am to 8pm. Calls are free, including from mobiles or visit www.macmillan.org.uk